Compare Quanta Services Inc (PWR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs TransMedics Group Inc — how do they compare? Quanta Services Inc trades at $700.31 (market cap $103.03B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Quanta Services Inc is far larger — about 37.6× TransMedics Group Inc's market cap, and Quanta Services Inc pays a 0.06% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quanta Services Inc for 62 Days and TransMedics Group Inc for 24 Days on average.
| PWR | TMDX | |
|---|---|---|
Market Cap | $103.03B | $2.74B |
Volume | 977,892 | 949,331 |
Sector | Industrials | Health |
52-Week High | $785.24 | $150.42 |
52-Week Low | $412.21 | $61.99 |
Typical Hold Time | 62 Days | 24 Days |
Enterprise Value | $109.13B | $3.13B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PWR trades at $705.94, up 0.69% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, reaching $28.48B in 2025, though valuation multiples like a P/E of 78.41 appear elevated. Positive sentiment is driven by a record $53B backlog and AI infrastructure demand, as highlighted in recent Zacks reports.
Outlook remains positive given earnings momentum and sector tailwinds, but high valuation and execution risks from rapid expansion warrant caution. The consensus price target of $802.08 implies upside, yet investors should monitor margin sustainability and competitive pressures in the construction and electrical services sector.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
